Drug manufacturer Insys Therapeutics Inc. has agreed to pay $225 million in order to end federal investigations into allegations that it used illegal marketing schemes to push a powerful opioid-based painkiller.
Federal prosecutors allege that company used kickbacks and veiled bribes in order to sell a fentanyl spray, called Susbys, which is designed for cancer patients suffering from severe pain.
The company agreed to pay a $2 million criminal fine and forfeit $28 million. Additionally, Insys agreed to pay $195 million to settle civil allegations, according to the Associated Press.
